Related references
Note: Only part of the references are listed.Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
MARC DE HERT et al.
World Psychiatry (2015)
Clozapine impairs insulin action by up-regulating akt phosphorylation and Ped/Pea-15 protein abundance
Fabio Panariello et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients
N. Hepgul et al.
PSYCHOLOGICAL MEDICINE (2012)
Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation
Anthony C. Vernon et al.
BIOLOGICAL PSYCHIATRY (2011)
Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis
V. L. Albaugh et al.
MOLECULAR PSYCHIATRY (2011)
Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats
Miwako Shobo et al.
LIFE SCIENCES (2011)
THE EFFECTS OF NEUROPSYCHIATRIC DRUGS ON GLYCOGEN SYNTHASE KINASE-3 SIGNALING
L. P. Sutton et al.
NEUROSCIENCE (2011)
Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model
Araba F. Chintoh et al.
SCHIZOPHRENIA RESEARCH (2009)
Clozapine and high-dose olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison
Sanjiv Kumra et al.
BIOLOGICAL PSYCHIATRY (2008)
First- V. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis
M. Smith et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Olanzapine inhibits glycogen synthase kinase-3β:: An investigation by docking simulation and experimental validation
Mohammad K. Mohammad et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Comorbid somatic illnesses in patients with severe mental disorders:: Clinical, policy, and research challenges
W. Wolfgang Fleischhacker et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Tissue-specific role of glycogen synthase kinase 3β in glucose homeostasis and insulin action
Satish Patel et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Glycogen synthase kinase 3α-specific regulation of murine hepatic glycogen metabolism
Katrina MacAulay et al.
CELL METABOLISM (2007)
The role of GSK3 in glucose homeostasis and the development of insulin resistance
Jongsoon Lee et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats
SuJean Choi et al.
LIFE SCIENCES (2007)
Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects
Sunmin Park et al.
LIFE SCIENCES (2007)
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment
J. Minet-Ringuet et al.
MOLECULAR PSYCHIATRY (2007)
Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia
L. M. Spelman et al.
DIABETIC MEDICINE (2007)
IGF-binding protein-2 protects against the development of obesity and insulin resistance
Stephen B. Wheatcroft et al.
DIABETES (2007)
Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics
Xiaohua Li et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2007)
Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics
Cong-jie Wang et al.
BIOLOGICAL PSYCHIATRY (2006)
Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells
J Engl et al.
MOLECULAR PSYCHIATRY (2005)
Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling
G Canettieri et al.
CELL METABOLISM (2005)
Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000
RJ Koopman et al.
ANNALS OF FAMILY MEDICINE (2005)
Metabolic disturbance in first-episode schizophrenia
JH Thakore
BRITISH JOURNAL OF PSYCHIATRY (2004)
The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia
MCM Ryan et al.
LIFE SCIENCES (2004)
Fatal olanzapine-induced hyperglycemic ketoacidosis
J Avella et al.
AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY (2004)
Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes
AM Valverde et al.
DIABETES (2003)
Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy
S Kapur et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Metabolic syndrome in patients with schizophrenia
T Heiskanen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Fatal olanzapine-induced ketoacidosis
EF Torrey et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Comparative effects of the antipsychotics sulpiride or risperidone in rats - I: Bodyweight, food intake, body composition, hormones and glucose tolerance
T Baptista et al.
BRAIN RESEARCH (2002)
Diabetes: The importance of the liver
GA Rutter
CURRENT BIOLOGY (2000)
Causes of the excess mortality of schizophrenia
S Brown et al.
BRITISH JOURNAL OF PSYCHIATRY (2000)
Obesity and insulin resistance
BB Kahn et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Cellular mechanisms of insulin resistance
GI Shulman
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
